amoxicillin/clavulanate potassium 1gm — Competitive Intelligence Brief

amoxicillin/clavulanate potassium 1gm (amoxicillin/clavulanate potassium 1gm) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamase Infectious Disease Small molecule

Target snapshot

amoxicillin/clavulanate potassium 1gm (amoxicillin/clavulanate potassium 1gm) — GlaxoSmithKline. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amoxicillin/clavulanate potassium 1gm TARGET	amoxicillin/clavulanate potassium 1gm	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
high dose amoxicillin/clavulanate	high dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase
Piperacillin / Tazobactam Injection	Piperacillin / Tazobactam Injection	Rambam Health Care Campus	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins; bacterial beta-lactamase enzymes
standard dose amoxicillin/clavulanate	standard dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Amoxicillin clavulanic	Amoxicillin clavulanic	Hospital Italiano de Buenos Aires	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Piperacillin-tazobactam combination product	Piperacillin-tazobactam combination product	Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Piperacillin-tazobactam	Piperacillin-tazobactam	University Hospital, Bordeaux	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class